Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Druggability Technologies Appoints Louis Scotti as Chief Business Development Officer

Abstract:
Druggability Technologies Holdings Limited (DRGT), a privately held biotechnology platform company, today announced the appointment of Louis Scotti to the newly created position of Chief Business Development Officer. Mr. Scotti will be responsible for all business development activities and managing the company's numerous existing collaborations for its NanoActive™ technology platform, which significantly improves the solubility, permeability and pharmacokinetics of diverse chemical and biological compounds.

Druggability Technologies Appoints Louis Scotti as Chief Business Development Officer

Dublin, Ireland | Posted on August 3rd, 2012

"We are pleased that Mr. Scotti has joined our senior management team at DRGT," said Gabor Heltovics, CEO of DRGT. "With his long track record of concluding major drug development collaborations with pharmaceutical and biotechnology companies worldwide, Mr. Scotti will be an integral part of our efforts to expand the successful application of our proprietary technologies."

Mr. Scotti most recently served in senior commercial roles during a 12-year career at Arena Pharmaceuticals, Inc., a NASDAQ listed company that recently received FDA approval of Belviq® (lorcaserin HCl), the first prescription weight-loss treatment approved by FDA in 13 years. At Arena, Mr. Scotti held several positions, including Vice President Business Development, Vice President Marketing & Business Development and Vice President Commercial Planning. He was directly responsible for corporate alliances with major pharmaceutical companies such as Merck, J&J and Eli Lilly. Previously, Mr. Scotti was CEO of ProtoMed, Inc. and earlier headed licensing activities as executive director for Ligand Pharmaceuticals, Inc. Mr. Scotti holds a B.S.E. in biomedical engineering from the University of Pennsylvania.

####

About Druggability Technologies Holdings Limited (DRGT)
Headquartered in Dublin, Ireland, DRGT, through its subsidiaries, is developing and commercializing its proprietary NanoActive™ high throughput technology platform. This platform delivers significant improvements in compound solubility, permeability and pharmacokinetics that can be applied across a diverse universe of chemical and biological compounds.

The Company's experience in improving the bioavailability and kinetic profile of drugs is born of a heritage of three decades of scientific and industrial knowledge gained through successful commercial ventures in bio- and chemo-informatics, combinatorial chemistry, chemical genomics, flow chemistry, colloidal chemistry, and nanotechnology.

For more information, please click here

Contacts:
Druggability Technologies Holdings Ltd.
Gabor Heltovics
Chief Executive Officer
+36-1-8808-468
+36-1-8808-501 (FAX)

Copyright © Marketwire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Nanoscale worms provide new route to nano-necklace structures March 29th, 2015

Solving molybdenum disulfide's 'thin' problem: Research team increases material's light emission by twelve times March 29th, 2015

A first glimpse inside a macroscopic quantum state March 28th, 2015

DFG to Establish One Clinical Research Unit and Five Research Units: New Projects to Investigate Complications in Pregnancy, Particle Physics, Nanoparticles, Implants and Transport Planning / Approximately 13 Million Euros in Funding for an Initial Three-Year Period March 28th, 2015

Nanomedicine

Novel nanoparticle therapy promotes wound healing March 27th, 2015

Graphene reduces wear of alumina ceramic March 26th, 2015

Application of Graphene Oxide in Body Implants in Iran March 26th, 2015

Nanorobotic agents open the blood-brain barrier, offering hope for new brain treatments March 25th, 2015

Announcements

Nanoscale worms provide new route to nano-necklace structures March 29th, 2015

Solving molybdenum disulfide's 'thin' problem: Research team increases material's light emission by twelve times March 29th, 2015

A first glimpse inside a macroscopic quantum state March 28th, 2015

DFG to Establish One Clinical Research Unit and Five Research Units: New Projects to Investigate Complications in Pregnancy, Particle Physics, Nanoparticles, Implants and Transport Planning / Approximately 13 Million Euros in Funding for an Initial Three-Year Period March 28th, 2015

Appointments/Promotions/New hires/Resignations/Deaths

Nanofilm Appoints Senior Sales/Marketing Executives: Don Tecco, Director of Optical Sales, North America and Rex Talbott, Business Director Optical Products March 23rd, 2015

KIT Increases Commitment in Asia: DAAD Funds Two New Projects: Strategic Partnerships with Chinese Universities and Communi-cation Technologies Network February 22nd, 2015

SouthWest Nanotechnologies CEO Dave Arthur Appointed to the Board of Affiliates of Rice University Professional Science Master’s Program February 13th, 2015

Nexeon Board Changes Announced January 29th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE